Voyager Therapeutics (NASDAQ:VYGR) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Voyager Therapeutics (NASDAQ:VYGR) from a buy rating to a hold rating in a research note published on Sunday morning.

Other equities analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, October 24th. Wedbush lowered their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $17.43.

Voyager Therapeutics Trading Down 2.6 %

Shares of VYGR stock opened at $6.83 on Friday. Voyager Therapeutics has a 12 month low of $5.71 and a 12 month high of $11.72. The stock has a market cap of $372.44 million, a P/E ratio of 24.39 and a beta of 0.89. The company has a 50 day simple moving average of $6.62 and a two-hundred day simple moving average of $7.53.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. Ameritas Investment Partners Inc. raised its holdings in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares in the last quarter. Plato Investment Management Ltd purchased a new stake in Voyager Therapeutics during the first quarter valued at $38,000. China Universal Asset Management Co. Ltd. lifted its position in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the 3rd quarter worth $74,000. Finally, SG Americas Securities LLC bought a new stake in shares of Voyager Therapeutics in the 2nd quarter worth about $85,000. 48.03% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.